Moxifloxacin: new preparation. A me-too with more cardiac risks

(1) Moxifloxacin is the fourth fluoroquinolone to be licensed in France with indications covering ENT and respiratory tract infections. (2) In community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis, moxifloxacin seems no more effective than other fluoroquinolones available in France (with which it has not been compared) or the other antibiotics with which it has been compared. (3) Moxifloxacin has the usual adverse effects of fluoroquinolones, but carries a greater risk of QT prolongation than ciprofloxacin, levofloxacin and ofloxacin.